logo-loader

Allergy Therapeutics raises £10.6mln to fund expansion of late-stage PQ Grass study

Last updated: 05:35 19 Jul 2018 EDT, First published: 02:35 19 Jul 2018 EDT

girl with hay fever
The phase III PQ Grass trial is pencilled in the diary for the second half of 2019

Allergy Therapeutics plc (LON:AGY) has raised £10.6mln to fund the expansion of the phase III clinical trial of its grass pollen-induced hay fever immunotherapy.

The AIM-quoted firm placed 40mln new shares at 26.5p each – slightly below yesterday’s closing price of 28p.

READ: AGY full-year revenues to rise despite weak pollen season

“Allergy Therapeutics is poised for a transformational period of growth both with our marketed products and our R&D pipeline,” said chief executive Manuel Llobet.

“With this successful placing and subscription, we will expand our planned phase III PQ Grass trial, scheduled to start in H2 2019, including a project to analyse pollen trends in the US to maximise the exposure of patients to grass pollen.

“We will also support the Acarovac phase II trial and, looking further out, further progress our diversified pipeline of patient-friendly, convenient to use products including Polyvac Peanut.”

Earlier this year, Allergy hailed the “extremely positive results” from the phase II trial of PQ Grass, with those taking the drug showing “a highly statistically significant” reduction in symptoms compared to patients in the placebo arm of the study.

READ: AGY readies PQ Grass for phase III trial

Allergy already has a treatment for grass pollen-induced allergic rhinitis – a fancy term for hay fever. But this new formulation is an injection which includes an adjuvant to help boost the body’s immune response.

One of the key target markets for PQ Grass is the US, where it would be the first immunotherapy injection to be registered and where peak grass vaccine sales could be US$300-$400mln a year.

As well as funding the late-stage PQ Grass trial, the cash will also be used to part-fund the phase II study of Acarovac, the company’s dust mite allergy treatment.

Allergy share dipped 2.5% to 27p on Thursday morning.

--Updates for completion of placing, share price--

Coniagas Battery Metals secures new key ground with focus on...

Coniagas Battery Metals (TSX-V:COS) CEO Frank Basa joined Steve Darling from Proactive to announce the company's strategic acquisition of key ground near SOQUEM’s Cardinal Property, located 80 km southeast of Chibougamau, Quebec. This acquisition underscores Coniagas’ commitment to capitalizing...

28 minutes ago